Management of work-related asthma

被引:20
作者
Smith, Andrew M. [1 ]
Bernstein, David I. [1 ]
机构
[1] Univ Cincinnati, Dept Internal Med, Div Immunol, Cincinnati, OH 45267 USA
关键词
Work-related asthma; occupational asthma; work-exacerbated asthma; irritant-induced asthma; STANDARDIZED LATEX EXTRACT; IRRITANT-INDUCED ASTHMA; NATURAL-RUBBER LATEX; OCCUPATIONAL ASTHMA; DOUBLE-BLIND; DIPHENYLMETHANE DIISOCYANATE; RESPIRATORY SYMPTOMS; IMMUNOGLOBULIN G4; FATAL ASTHMA; IMMUNOTHERAPY;
D O I
10.1016/j.jaci.2008.12.1129
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
The physician managing work-related asthma (WRA) assumes many roles. The first is to confirm an accurate diagnosis, recognizing that WRA has multiple phenotypes, including sensitizer-induced occupational asthma (OA) caused by high-molecular-weight (HMW) proteins or low-molecular-weight (LMW) chemicals; irritant-induced asthma; and work-exacerbated asthma. Pharmacotherapy for WRA is identical to nonwork-related asthma and should be guided by current asthma guidelines emphasizing control of both asthma impairment and risk domains. It is well established that the majority of workers diagnosed with OA caused by sensitizers experience persistent asthma after leaving the workplace. However, the long-term risk of persistent unremitting asthma can be prevented in a minority of cases, particularly with OA caused by LMW sensitizers, by establishing an early diagnosis of OA and reducing or eliminating exposure. The physician consultant may advise employers on workplace interventions needed to minimize effectively an affected employee's exposure to a causative agent or condition, and what measures are required to prevent new cases of WRA (ie, primary prevention). Although allergen immunotherapy has a putative role in treating and preventing WRA caused by HMW sensitizers, further study is needed. Q Allergy Clin Immunol 2009;123:551-7.)
引用
收藏
页码:551 / 557
页数:7
相关论文
共 64 条
[1]   FEV1 decline in occupational asthma [J].
Anees, W. ;
Moore, V. C. ;
Burge, P. S. .
THORAX, 2006, 61 (09) :751-755
[2]  
[Anonymous], 2006, GLOB STRAT ASTHM MAN
[3]  
ARMENTIA A, 1990, ANN ALLERGY, V65, P265
[4]   American Thoracic Society Statement: Occupational contribution to the burden of airway disease [J].
Balmes, J ;
Becklake, M ;
Blanc, P ;
Henneberger, P ;
Kreiss, K ;
Mapp, C ;
Milton, D ;
Schwartz, D ;
Toren, K ;
Viegi, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (05) :787-797
[5]   PERSISTENCE OF TOLUENE DIISOCYANATE-INDUCED ASTHMA DESPITE NEGLIGIBLE WORKPLACE EXPOSURES [J].
BANKS, DE ;
RANDO, RJ ;
BARKMAN, HW .
CHEST, 1990, 97 (01) :121-125
[6]   Global strategy for asthma management and prevention: GINA executive summary [J].
Bateman, E. D. ;
Hurd, S. S. ;
Barnes, P. J. ;
Bousquet, J. ;
Drazen, J. M. ;
FitzGerald, M. ;
Gibson, P. ;
Ohta, K. ;
O'Byrne, P. ;
Pedersen, S. E. ;
Pizzichini, E. ;
Sullivan, S. D. ;
Wenzel, S. E. ;
Zar, H. J. .
EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (01) :143-178
[7]   Are we closer to developing threshold limit values for allergens in the workplace? [J].
Baur, X .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2003, 90 (05) :11-18
[8]  
Bernstein D.I., 2006, Asthma in the workplace, V3rd, P1
[9]   Diisocyanate antigen-stimulated monocyte chemoattractant protein-1 synthesis has greater test efficiency than specific antibodies for identification of diisocyanate asthma [J].
Bernstein, DI ;
Cartier, A ;
Côté, J ;
Malo, JL ;
Boulet, LP ;
Wanner, M ;
Milot, J ;
L'Archevéque, J ;
Trudeau, C ;
Lummus, Z .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (04) :445-450
[10]   THE LOW-PREVALENCE OF OCCUPATIONAL ASTHMA AND ANTIBODY-DEPENDENT SENSITIZATION TO DIPHENYLMETHANE DIISOCYANATE IN A PLANT ENGINEERED FOR MINIMAL EXPOSURE TO DIISOCYANATES [J].
BERNSTEIN, DI ;
KORBEE, L ;
STAUDER, T ;
BERNSTEIN, JA ;
SCINTO, J ;
HERD, ZL ;
BERNSTEIN, IL .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1993, 92 (03) :387-396